Breast Cancer Stage II Clinical Trial
Official title:
Improving Support for Older Patients Receiving Neo/Adjuvant Chemotherapy for Breast Cancer Using a Novel Social Media Intervention
NCT number | NCT02639208 |
Other study ID # | 15-326 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 8, 2016 |
Est. completion date | August 6, 2021 |
Verified date | August 2021 |
Source | Dana-Farber Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The number of patients 60 and older with breast cancer is increasing as our population ages. Despite the fact that the majority of breast cancers occur in patients 60 and over, these patients are consistently under-represented in clinical trials. Because patients 60 and older are an under-studied group, investigators do not have detailed information on the side effects and experiences for these patients receiving chemotherapy. Understanding the side effects patients receiving chemotherapy experience is an important part of this study. In addition, past research has shown that having poor social support can affect quality of life, mood, and outcomes for people with cancer. However, few studies in the past have focused on improving the quality of life and support systems that patients have while they receive treatment. This research study is evaluating how engaging in an online support community may improve the experience of older patients receiving chemotherapy.
Status | Completed |
Enrollment | 47 |
Est. completion date | August 6, 2021 |
Est. primary completion date | May 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 60 Years and older |
Eligibility | Inclusion Criteria: - Participants must be women =60 years age with histologically or cytologically confirmed, stage I-III breast cancer with a treatment plan that includes any neoadjuvant or adjuvant chemotherapy(either in the context of standard treatment or a clinical trial and including chemotherapy, treatments targeting the human epidermal growth factor receptor protein 2 [HER2]), hormonal therapy or radiation. - Enrollment must occur according to one of the following: (1) For those receiving chemotherapy/infusional therapy, patients must enroll during the 4 weeks prior to or on the day of treatment initiation, (2) For those enrolling during hormonal therapy and/or radiation, patients must enroll within 6 months of diagnosis of breast cancer, defined as the date of initial biopsy. Patient may be receiving hormonal therapy, radiation therapy, or both at the same time of enrollment, (3) Patients who did not enroll during their chemotherapy are still eligible to enroll during subsequent hormonal therapy or radiation as long as it is within 6 months of diagnosis. - Participants must be approached before start of treatment. Patients must be able to understand, read, and write in English and be able to understand and have willingness to sign a written informed consent document. - Patients are eligible regardless of ECOG performance status, life expectancy or, organ/marrow function. - Patients must have the ability to access the internet at least once per week, and this can occur in the patient's home, relatives' homes, work setting, or Dana-Farber (in addition to coffee shops, libraries, etc if applicable). Having a computer is not required. An iPad will be provided to any patient who needs one for the duration of the study. Exclusion Criteria: - Patients with metastatic breast cancer are not eligible to participate. - Participants who have started their treatment plan are not eligible. - Those unable to understand, read, or write in English are not eligible. - Men are not eligible for this study. |
Country | Name | City | State |
---|---|---|---|
United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Dana-Farber Cancer Institute | CURE Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility/ Rate of Participant Login - PLM | We will describe the degree of patient use of the PLM platforms and the associations of short and longer term PLM use with patient characteristics | 4-6 months | |
Secondary | Rate of Usability of PLM | Usability (how useful they found PLM, what parts of the site they used, etc.) will be assessed using a patient experience survey at the end of the study | 6 Months | |
Secondary | Rate of Overall Satisfaction with PLM | Satisfaction with the PLM experience wil be assessed using a 'patient experience' survey at the end of the study | 6 Months | |
Secondary | Rate of Desirability with PLM | Desirability (how much they enjoyed using PLM, etc) wil be assessed using a patient experience survey at the end of the study | 6 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05528263 -
Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)
|
N/A | |
Recruiting |
NCT03270072 -
The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients
|
||
Terminated |
NCT03723863 -
Occupational Therapist-Led Work Intervention in Facilitating Work Maintenance or Re-entry to the Workforce in Patients With Stage I to III Breast Cancer Undergoing Chemotherapy
|
N/A | |
Completed |
NCT00393341 -
Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer
|
N/A | |
Recruiting |
NCT05558722 -
Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04180579 -
Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients
|
N/A | |
Recruiting |
NCT03879577 -
Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT03058939 -
Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05877859 -
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
|
||
Recruiting |
NCT05296746 -
Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT05774886 -
Implantable Microdevice for TNBC - Pilot Study
|
Phase 1 | |
Completed |
NCT01599039 -
Study the Usefulness of Bio-impedance Spectroscopy in the Early Assessment of Breast Cancer Related Lymphoedema
|
N/A | |
Unknown status |
NCT01352494 -
Neoadjuvant Chemotherapy With Docetaxel and Gemcitabine in Locally Advanced Breast Cancer
|
Phase 2 | |
Completed |
NCT03578627 -
Stress and Immunity Breast Cancer Project
|
N/A | |
Recruiting |
NCT06275126 -
Optimizing Surgical Decisions in Young Adults With Breast Cancer
|
N/A | |
Not yet recruiting |
NCT05724758 -
Patient Reported Outcomes After Oncoplastic Breast Conserving Surgery
|
||
Active, not recruiting |
NCT03766009 -
Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making
|
N/A | |
Recruiting |
NCT05406531 -
The Effectiveness of Psychological Interventions in Psycho-neuroendocrine-immune Network in Breast Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03609047 -
Adjuvant Palbociclib in Elderly Patients With Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05898789 -
Virtual Rehabilitation for Cancer Survivors
|
N/A |